MED BIOGENE

Med BioGene Inc. (MBI) is a life science company based in Vancouver, British Columbia, that is currently focused on managing the license and rights to GeneFx® Lung (formerly, LungExpress Dx), a proprietary gene expression-based test for early-stage non-small-cell lung cancer. GeneFx Lung is expected to provide better-informed and personalized treatment decisions to assist in the selection of patients for adjuvant chemotherapy. MBI has partnered with Precision Therapeutics for the global commercialization of GeneFx Lung. MBI's common shares are traded on the TSX Venture Exchange.